Shopping Cart 0
Cart Subtotal
AED 0

LFB SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

LFB SA (LFB), a subsidiary of Ministry of Health France is a manufacturer and producer of biological medicinal products. The company offers immunology, haemostasis, perinatal and intensive care and adverse effect reporting products. Its services include bio production and technology transfer services. The company's bio production services comprise plasma derivatives and contract work, and biotechnology services. It operates in Morocco, Togo, Algeria, Tunisia, Libya, Sudan, Yemen, Saudi Arabia, Israel, Turkey, Iran Kuwait, Hong Kong, Australia, Brazil, France, Mexico, the UAE, the UK and the US, among others. LFB is headquartered in Paris, France.

LFB SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LFB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

LFB SA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

GamaMabs Pharma Raises USD 4.2 Million In Seed Financing 11

Partnerships 12

LFB Forms Joint Venture with US WorldMeds 12

Yabao Pharma Enters into Distribution Agreement with LFB Biomedicaments 13

LFB Forms Joint Venture with BPI France 14

Shin Poong Pharma Forms Joint Venture With Laboratoire Francais De Fractionnement 15

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 16

Licensing Agreements 17

TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 17

Biomed Lublin Enters into Licensing Agreement with Laboratoire Francais 18

LFB Enters Into Licensing Agreement with STROVI Tel 19

Equity Offering 20

LFB to Raise USD261 Million in Private Placement of Shares 20

rEVO Biologics Withdraws Initial Public Offering of Shares for USD54 Million 21

Acquisition 23

LFB Acquires CAF-DCF 23

LFB SA-Key Competitors 24

LFB SA-Key Employees 25

LFB SA-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Joint Venture 27

Recent Developments 28

Corporate Communications 28

Dec 21, 2017: Denis DELVAL is Appointed CEO of LFB 28

Product News 29

02/21/2017: TG Therapeutics Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology 29

Product Approvals 30

Jan 06, 2017: FDA Accepts For Review LFB's BLA For Its Recombinant Factor VII 30

Clinical Trials 31

May 19, 2017: TG Therapeutics Announces Data on TG-1101 at the Upcoming 14th International Conference on Malignant Lymphoma 31

May 17, 2017: TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 32

Apr 28, 2017: TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting 33

Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TG-1101 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 34

Mar 06, 2017: TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) 35

Mar 03, 2017: TG Therapeutics Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting 37

Jan 11, 2017: TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

LFB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

LFB SA, Pharmaceuticals & Healthcare, Key Facts 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Deals By Therapy Area, 2012 to YTD 2018 9

LFB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

GamaMabs Pharma Raises USD 4.2 Million In Seed Financing 11

LFB Forms Joint Venture with US WorldMeds 12

Yabao Pharma Enters into Distribution Agreement with LFB Biomedicaments 13

LFB Forms Joint Venture with BPI France 14

Shin Poong Pharma Forms Joint Venture With Laboratoire Francais De Fractionnement 15

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 16

TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 17

Biomed Lublin Enters into Licensing Agreement with Laboratoire Francais 18

LFB Enters Into Licensing Agreement with STROVI Tel 19

LFB to Raise USD261 Million in Private Placement of Shares 20

rEVO Biologics Withdraws Initial Public Offering of Shares for USD54 Million 21

LFB Acquires CAF-DCF 23

LFB SA, Key Competitors 24

LFB SA, Key Employees 25

LFB SA, Other Locations 26

LFB SA, Subsidiaries 26

LFB SA, Joint Venture 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

LFB SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

LFB SA (LFB), a subsidiary of Ministry of Health France is a manufacturer and producer of biological medicinal products. The company offers immunology, haemostasis, perinatal and intensive care and adverse effect reporting products. Its services include bio production and technology transfer services. The company's bio production services comprise plasma derivatives and contract work, and biotechnology services. It operates in Morocco, Togo, Algeria, Tunisia, Libya, Sudan, Yemen, Saudi Arabia, Israel, Turkey, Iran Kuwait, Hong Kong, Australia, Brazil, France, Mexico, the UAE, the UK and the US, among others. LFB is headquartered in Paris, France.

LFB SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LFB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

LFB SA, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

GamaMabs Pharma Raises USD 4.2 Million In Seed Financing 11

Partnerships 12

LFB Forms Joint Venture with US WorldMeds 12

Yabao Pharma Enters into Distribution Agreement with LFB Biomedicaments 13

LFB Forms Joint Venture with BPI France 14

Shin Poong Pharma Forms Joint Venture With Laboratoire Francais De Fractionnement 15

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 16

Licensing Agreements 17

TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 17

Biomed Lublin Enters into Licensing Agreement with Laboratoire Francais 18

LFB Enters Into Licensing Agreement with STROVI Tel 19

Equity Offering 20

LFB to Raise USD261 Million in Private Placement of Shares 20

rEVO Biologics Withdraws Initial Public Offering of Shares for USD54 Million 21

Acquisition 23

LFB Acquires CAF-DCF 23

LFB SA-Key Competitors 24

LFB SA-Key Employees 25

LFB SA-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Joint Venture 27

Recent Developments 28

Corporate Communications 28

Dec 21, 2017: Denis DELVAL is Appointed CEO of LFB 28

Product News 29

02/21/2017: TG Therapeutics Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology 29

Product Approvals 30

Jan 06, 2017: FDA Accepts For Review LFB's BLA For Its Recombinant Factor VII 30

Clinical Trials 31

May 19, 2017: TG Therapeutics Announces Data on TG-1101 at the Upcoming 14th International Conference on Malignant Lymphoma 31

May 17, 2017: TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 32

Apr 28, 2017: TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting 33

Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TG-1101 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 34

Mar 06, 2017: TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) 35

Mar 03, 2017: TG Therapeutics Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting 37

Jan 11, 2017: TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

LFB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

LFB SA, Pharmaceuticals & Healthcare, Key Facts 2

LFB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LFB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LFB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LFB SA, Deals By Therapy Area, 2012 to YTD 2018 9

LFB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

GamaMabs Pharma Raises USD 4.2 Million In Seed Financing 11

LFB Forms Joint Venture with US WorldMeds 12

Yabao Pharma Enters into Distribution Agreement with LFB Biomedicaments 13

LFB Forms Joint Venture with BPI France 14

Shin Poong Pharma Forms Joint Venture With Laboratoire Francais De Fractionnement 15

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 16

TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 17

Biomed Lublin Enters into Licensing Agreement with Laboratoire Francais 18

LFB Enters Into Licensing Agreement with STROVI Tel 19

LFB to Raise USD261 Million in Private Placement of Shares 20

rEVO Biologics Withdraws Initial Public Offering of Shares for USD54 Million 21

LFB Acquires CAF-DCF 23

LFB SA, Key Competitors 24

LFB SA, Key Employees 25

LFB SA, Other Locations 26

LFB SA, Subsidiaries 26

LFB SA, Joint Venture 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

LFB SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.